Drugs / VCT220
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07652047 | May 2026 → Mar 2027 expected | obesity disorder | Corxel Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07349381 | Mar → Jun 2026 overdue | obesity disorder, type 2 diabetes mellitus | Vincentage Pharma Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07347808 | Dec 2025 → Jan 2026 | obesity disorder | Vincentage Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07056842 | Jul → Aug 2025 | obesity disorder | Vincentage Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07065058 | Jul 2025 | obesity disorder | Vincentage Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06938529 | Apr → Jul 2025 | obesity disorder | Vincentage Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07360275 | Mar → Oct 2026 expected | hypertensive disorder | Vincentage Pharma Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07340320 | Feb → Dec 2026 expected | type 2 diabetes mellitus | Corxel Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07011797 | Jun 2025 → Mar 2026 | obesity disorder | Corxel Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT06569355 | Dec 2023 → Jul 2024 | obesity disorder | Vincentage Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06939296 | Dec 2024 → Nov 2025 overdue | obesity disorder | Vincentage Pharma Co., Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCT220 | “CX11 (VCT220)” NCT07349381 ↗ |
| Known as | CX11 | “This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of VCT220 (other name: CX11) in subjects with moderate renal impairment...” NCT07347808 ↗ |
| Action | Activate | “GLP-1R agonist” NCT06569355 ↗ |
| Modality | Small molecule | “A small molecule GLP-1R agonist tablet” NCT06569355 ↗ |
| Route | Oral | “orally administration” NCT06569355 ↗ |